SELLAS Life Sciences
33 hedge funds and large institutions have $6.76M invested in SELLAS Life Sciences in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.
5,392% more call options, than puts
Call options by funds: $5.27M | Put options by funds: $96K
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
39% more capital invested
Capital invested by funds: $4.86M → $6.76M (+$1.9M)
10% more funds holding
Funds holding: 30 → 33 (+3)
1.34% more ownership
Funds ownership: 7.06% → 8.41% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$970K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$619K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$108K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$76.7K |
| 5 |
Renaissance Technologies
New York
|
+$73.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EH
Equitable Holdings
New York
|
-$242K |
| 2 |
Millennium Management
New York
|
-$127K |
| 3 |
Jane Street
New York
|
-$34.2K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$18K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.1K |
SLS Hedge Fund Activity: Q3 2024 in Review
33 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2024, worth a combined $6.76M — up 39% from $4.86M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLS positions and 4 closed out — a net gain of 4 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $970K. The largest seller was Equitable Holdings, cutting an estimated $242K.
- 33 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2024, up from 30 in Q2 2024.
- Funds reported $6.76M of SELLAS Life Sciences stock for Q3 2024, up 39% quarter-over-quarter.
- 8 funds opened new SELLAS Life Sciences positions in Q3 2024 and 4 closed out, a net change of +4 holders.
- The largest SELLAS Life Sciences buyer in Q3 2024 was Anson Funds Management, an estimated $970K added.
- The largest SELLAS Life Sciences seller in Q3 2024 was Equitable Holdings, an estimated $242K sold.
Based on aggregated 13F filings for Q3 2024.